SUNY Upstate’s Dr. Stephen Thomas Selected as PI for Pfizer/BioNTech Phase 3 Vaccine Trial

SUNY Upstate’s Dr. Stephen Thomas Selected as PI for PfizerBioNTech Phase 3 Vaccine Trial

New York State Governor Andrew M. Cuomo recently announced the appointment of SUNY Upstate Medical University’s Stephen Thomas, MD, as lead principal investigator for the world-wide Pfizer/BioNTech vaccine trial, which recently revealed enormous potential with over 90 percent efficacy in preventing COVID-19. SUNY Upstate serves as one of the trial site organizations for the Phase 3, worldwide clinical trial. Dr. Thomas serves as Upstate’s Chief of Infectious Disease and supports Pfizer and BioNTech as they prepare vaccine trial data for submission to regulatory agencies including the U.S. Food and Drug Administration (FDA). TrialSite congratulates Dr. Stephen Thomas.

A Notable Role

An important role, Governor Cuomo declared New York’s medical experts are second to none and from the very beginning of this pandemic, we have relied on their vast knowledge and expertise to inform our response. I’m glad Pfizer is doing the same.” The Gov. continued, “It’s great news that Pfizer/BioNTech is seeing positive results from its vaccine trial, and I’m proud one of New York’s foremost infectious disease experts have been selected to lead its worldwide vaccine trial. On behalf of the family of New York, I would like to thank Dr. Thomas for his work fighting the invisible enemy.”

The Trial Site

SUNY Upstate has enrolled over 300 adult volunteers in this clinical trial. Soon another study commences involving younger volunteers and Upstate has been selected to participate by the sponsors.

SUNY Upstate on the Move

In other news SUNY Upstate’s Frank Middleton, PhD and Quadrant Biosciences received New York State Department of Health and FDA approval for their pooled surveillance testing and individual saliva swab test. Both the individual test and the pooled test can be done using saliva swabs rather than by swabs inserted in a person’s nose. Upstate’s saliva test allows SUNY to process up to 200,000 COVID tests per week. To date, SUNY has conducted 378,488 COVID-19 tests on campuses with a positive rate of 0.47 percent.

Lead Research/Investigator

Stephen Thomas, MD, Professor Medicine, Professor of Microbiology and Immunology, Division Chief of Infectious Disease

Responses

This site uses Akismet to reduce spam. Learn how your comment data is processed.